Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
Analysts covering Pacific Biosciences of California have kept their fair value anchor essentially steady at about US$2.42 per share, while making small tweaks to the assumptions that support that figure. These updates reflect a recalibration of expectations around how the business might grow into that valuation, rather than a wholesale reset of where the stock should sit. As you read on, keep an eye on how these shifting inputs shape the story so you can stay tuned and know what to watch as the narrative around Pacific Biosciences evolves over time.
Recent published research tagged to the PAC ticker focuses on Grupo Aeroportuario del Pacífico rather than Pacific Biosciences of California, so there is very limited directly usable Street commentary for PACB right now. Still, you can take a few signals on sentiment style and risk focus that may be relevant as you think about how analysts might look at Pacific Biosciences’ valuation and execution.
🐂 Bullish Takeaways
Some research, such as the upgrade to Overweight from Neutral by JPMorgan analyst Guilherme Mendes with a price target of MXN 460, describes a willingness to back a company once concerns around factors like traffic trends and capital allocation are judged to be reflected in the share price. For Pacific Biosciences, that sort of stance would typically mean analysts are watching for clear execution and disciplined spending to support the fair value story rather than simply chasing momentum.
JPMorgan’s argument that a premium to sector peers can be warranted when there is a high quality, diversified portfolio and disciplined capital allocation highlights the kind of features analysts often reward. If Pacific Biosciences can show consistent execution, cost control and transparent capital deployment, the fair value anchor around US$2.42 could be framed as reasonable in the eyes of more constructive analysts.
🐻 Bearish Takeaways
Citi’s downgrade of GAP Airports and prior Underperform ratings elsewhere illustrate how quickly analysts can shift toward caution when they see limited upside versus their targets or rising near term risks. For a stock like Pacific Biosciences, that sort of stance would usually center on concerns that upside is already priced in, or that execution needs to catch up with expectations embedded in that US$2.42 fair value estimate.
The research flow around PAC shows that even when analysts acknowledge long term potential, they may prefer to sit at Neutral when they see issues such as subdued trends or questions on capital allocation. Translated to Pacific Biosciences, the main bear case is likely to cluster around how quickly the company can translate its opportunities into measurable progress, and whether current valuation leaves enough room if that progress is slower than some investors hope.
Story Continues
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!
NasdaqGS:PACB 1-Year Stock Price Chart
PacBio plans to work with the n-Lorem Foundation and EspeRare to apply long read whole genome sequencing to individualized antisense oligonucleotide therapies for ultra rare genetic diseases, contributing its sequencing technology, reagents, scientific expertise, and support for long read genome analysis in rare disease research.
The proposed rare disease collaboration is intended to use long read sequencing earlier in the drug development process. The goal is to reduce multiple sequential tests, speed up target validation, and support regulatory grade molecular characterization that can inform target identification and antisense oligonucleotide design feasibility.
PacBio reported that researchers at UW Medicine and Seattle Children’s, supported by the SUDC Foundation and in kind backing from PacBio, plan to use PacBio HiFi whole genome sequencing as a first line approach to study Sudden Unexplained Death in Childhood. The researchers plan to sequence each child and their parents to improve detection of complex variants, with the team joining the HiFi Solves Global Consortium.
PacBio announced CiFi, a community developed method that combines chromatin conformation capture with HiFi long read sequencing to generate chromosome scale, haplotype resolved genome assemblies from a single Revio sequencing run. This method is aimed at genome biology, biodiversity, and functional genomics projects where sample material or cost are constraints.
Fair Value: The fair value estimate in the model remains effectively unchanged at about US$2.42 per share.
Discount Rate: The discount rate used in the analysis is slightly higher at 10.65%, compared with 9.79% previously. This reflects a modestly higher required return in the model.
Revenue Growth: The revenue growth assumption in the model is marginally higher at 13.65%, up from 13.53%.
Net Profit Margin: The net profit margin assumption is slightly higher at 16.40%, compared with 15.69% in the prior model.
Future P/E: The future P/E multiple assumption applied to the terminal period is slightly lower at 27.63x, down from 28.30x.
Narratives on Simply Wall St let you connect the story you see for a company with the numbers you think make sense. You set out your view on future revenue, earnings, and margins, link that to a fair value, then compare it to the current share price to frame your decisions. Narratives live on the Community page, update as fresh news and earnings arrive, and give you a simple way to see how changing information might shift your fair value view over time.
If you want the full story behind the current fair value assumptions for Pacific Biosciences of California, it is worth reading the original Narrative in detail on Simply Wall St.
How long read sequencing collaborations, national genomics programs, and clinical lab uptake feed into recurring consumables revenue and the revenue growth assumptions in the model.
Why cost discipline, product development, and international uptake are key to the net margin, future P/E, and cash flow path that sit behind the US$2.42 fair value anchor.
Which risks, from funding dependence to competition and large project exposure, could challenge the earnings path and lead you to adjust your own fair value view.
You can read the full Narrative and track future updates directly on Simply Wall St here, and decide if the story and numbers line up with your own view on Pacific Biosciences of California: PACB: Long Read Sequencing Collaborations Will Support Future Rare Disease Upside. Curious how numbers become stories that shape markets? Explore Community Narratives
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PACB.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com